NYC Half Marathon

Today the FDA announced the approval of the immunotherapy Opdivo® (nivolumab) for the treatment of advanced squamous non-small cell lung cancer (NSCLC), making it the first immunotherapy approved for that indication.…

Now that Opdivo (nivolumab) has been FDA-approved for two cancer types, and potentially more in the coming months, many patients are wondering: what’s next? Bristol-Myers Squibb (BMS), the maker of Opdivo, has put out…

For melanoma patients, it was a very big deal in 2011 when the FDA approved the CTLA-4 blocking antibody ipilimumab (Yervoy®) for the treatment of advanced melanoma. “Ipi” was the first drug ever to improve survival…